Company News

  

Ajinomoto CELLiST Korea Co., Inc. (ACK) announced that it has enhanced their agreement with JSR Life Sciences, LLC (JSR) to facilitate the worldwide expansion of its biopharmaceutical cell culture media products. 

As part of the collaborative agreement, JSR is now able to offer its clients seven additional CELLiST products, in addition to the exclusive, co-branded Basal Media CHO-MX, throughout the US, Brazil, as well as European markets: 

• CELLiST Basal Media BASAL3

• CELLiST Basal Media BASAL10

• CELLiST Feed Media FEED2

• CELLiST Feed Media F7

• CELLiST AminoSupplement Cys1

• CELLiST AminoSupplement Cys2

• CELLiST Supplement Glycyl L-Tyrosine Dihydrate

Each CELLiST product is a novel, chemically-defined, and animal origin-free medium that exhibits higher antibody productivity in CHO cell lines than other products currently available on the market. [1] Ajinomoto will continue to manufacture and distribute these products to Asian markets. 

"Since 2014, we have been supplying high-quality culture media for biopharmaceuticals from our plant in South Korea,” said Nakai Yuta, President of Ajinomoto CELLiST Korea. “We are honored to have the opportunity to meet the needs of customers in Europe and the United States through this enhanced agreement with JSR. This collaboration is important to grow our culture media business into the second pillar of our amino acid business."

The global market for culture media, which plays a vital role in cell culture for biopharmaceutical research, development, and manufacturing, is experiencing robust growth. The increasing demand for antibody drugs, vaccines, and the expanding field of cell and gene therapies underscores the rising demand. By 2030, estimates project the market to exceed USD 10 billion, driven partly by the growing need for CHO cell line culture media.[2] 

“Ajinomoto is well-suited to manufacture and commercialize this culture media due to their 30+ years of experience in amino acid technology and the cell culture media industry,” stated JSR Life Sciences President Tim Lowery. “This new collaboration allows us to offer our clients a comprehensive product line for their biologics manufacturing needs throughout the Americas and Europe. Coupled with Ajinomoto’s critical access in the APAC region, we are able to provide access to these important products globally."

About Ajinomoto CELLiST Korea Co., Inc.

Established in 2014, Ajinomoto CELLiST Korea Co., Inc.(ACK) is a subsidiary of Ajinomoto Co., Inc., dedicated to the production of culture media under Good Manufacturing Practice (GMP) standards. Located in Incheon, South Korea, ACK operates a state-of-the-art plant specialized in manufacturing cell culture media for CHO cells and HEK293 cells. Additionally, ACK offers Contract Manufacturing Organization (CMO) services for media production. The CELLiST Solution Center (CSC), with branches in Korea, China, and India provides comprehensive troubleshooting and support services to customers worldwide.

https://www.ajinomotocellistkorea.com/en/ 

About JSR Life Sciences, LLC

A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR LS’s global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com

[1] Ajinomoto Co. and JSR research 

[2] Cell Culture Media Market Size, Share, Trends Report, 2030 (grandviewresearch.com)